Armata Pharmaceutics Announces Publication Of Paper In 'Communications Biology,' A Peer-Reviewed Journal From Nature Portfolio
Benzinga Newsdesk 6 months ago
News
The publication, titled, "Structural atlas of Pakpunavirus P7-1 reveals determinants of virion stability and genome ejection," describes the structure of phage P7-1, which is included in Armata's multi-phage cocktail,
The publication, titled, "Structural atlas of Pakpunavirus P7-1 reveals determinants of virion stability and genome ejection," describes the structure of phage P7-1, which is included in Armata's multi-phage cocktail, AP-PA02. Armata is developing AP-PA02 as a potential treatment for chronic respiratory infections due to Pseudomonas aeruginosa in people with cystic fibrosis (CF) and with non-cystic fibrosis bronchiectasis (NCFB). AP-PA02 has shown promising results in two Phase 2 clinical trials to date, SWARM-P.a. (NCT04596319) and Tailwind (NCT05616221). Armata remains focused on proving the clinical utility of phages as well as conducting bench science to deepen the knowledge of phage mechanism of action.